Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBH7XI)

• Drug Name: Pramiconazole Drug Info
• Synonyms: Azoline; Antifungals, Janssen Research Foundation; R-126638

Indication

Disease Entry	ICD 11	Status	REF
Dermatological disease	DA24.Y	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 3013050
  CAS Number: CAS 219923-85-0
  TTD Drug ID: DMBH7XI

Molecule-Related Drug Atlas

Drug(s) Targeting Candida Cytochrome P450 51 (Candi ERG11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[4]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[4]
Posaconazole	DMUL5EW	Aspergillosis	1F20	Approved	[5]
Ketoconazole	DMPZI3Q	Blastomycosis	1F22	Approved	[6]
Miconazole	DMPMYE8	Cutaneous candidiasis	1F23.14	Approved	[4]
Oxiconazole	DME7KRM	Tinea corporis	1F28.Y	Approved	[7]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[4]
Terconazole	DMJ13KI	Candidiasis	1F23	Approved	[8]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[9]
Tioconazole	DMNYPGS	Onychomycosis	EE12.1	Approved	[10]

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[11]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[12]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[3]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[14]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[14]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[15]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[16]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[17]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[18]

Drug(s) Affected By 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[19]
Calcidiol	DMN4CV5	Hypophosphatemia		Approved	[20]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[21]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[23]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[24]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[25]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[26]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[27]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Gene/Protein Processing	[3]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[3]

References

• [1] The efficacy of oral treatment with pramiconazole in pityriasis versicolor: a phase II a trial. Br J Dermatol. 2007 Jun;156(6):1385-8.
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
• [6] Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
• [7] Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
• [8] Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
• [9] Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
• [10] Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
• [11] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [12] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [13] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [14] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [15] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [16] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [17] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [18] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [19] DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
• [20] Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1973-81. doi: 10.1016/j.bbrc.2005.10.178. Epub 2005 Nov 7.
• [21] Actions of Vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan;136(1):20-6.
• [22] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [23] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [24] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [25] Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005 Jan;115(1):177-86.
• [26] 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res. 2005 Mar 15;65(6):2488-97.
• [27] Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
• [28] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.